keyword
Keywords indication and contra indicati...

indication and contra indications of drugs

https://read.qxmd.com/read/38268179/documentation-of-the-patient-characteristics-morbid-obesity-and-bariatric-surgery-in-the-hospital-information-system-and-the-influence-on-the-number-of-medication-related-problems
#1
JOURNAL ARTICLE
Jurjen S Kingma, Iris A M Brenkman, Marcel P H van den Broek, Patricia M L A van den Bemt, Karin Janssen, Catherijne A J Knibbe, Desirée M T Burgers
BACKGROUND: As a result of pharmacokinetic changes, individuals with morbid obesity and/or with bariatric surgery may require dose adjustments, additional monitoring or medication should be avoided. Clinical decision support (CDS) may provide automated alerts enabling correct prescribing but requires documentation of these patient characteristics in the Hospital Information System (HIS) to prevent medication-related problems (MRPs). OBJECTIVE: The primary objective is to determine the proportion of patients with documentation of the patient characteristics morbid obesity and bariatric surgery in the HIS...
January 24, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/36992862/pharmacotherapy-of-obesity-an-update-on-the-available-medications-and-drugs-under-investigation
#2
REVIEW
Marlene Chakhtoura, Rachelle Haber, Malak Ghezzawi, Caline Rhayem, Raya Tcheroyan, Christos S Mantzoros
UNLABELLED: Obesity is an epidemic and a public health threat. Medical weight management remains one of the options for the treatment of excess weight and recent advances have revolutionized how we treat, and more importantly how we will be treating obesity in the near future. Metreleptin and Setmelanotide are currently indicated for rare obesity syndromes, and 5 other medications (orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, semaglutide) are approved for non-syndromic obesity...
April 2023: EClinicalMedicine
https://read.qxmd.com/read/36824956/a-machine-learning-based-model-for-automated-recommendation-of-individualized-treatment-of-rifampicin-resistant-tuberculosis
#3
Lennert Verboven, Steven Callens, John Black, Gary Maartens, Kelly E Dooley, Samantha Potgieter, Ruben Cartuyvels, Smartt Team, Kris Laukens, Robin M Warren, Annelies Van Rie
Background Rifampicin resistant tuberculosis remains a global health problem with almost half a million new cases annually. In high-income countries patients empirically start a standardized treatment regimen, followed by an individualized regimen guided by drug susceptibility test (DST) results. In most settings, DST information is not available or is limited to isoniazid and fluoroquinolones. Whole genome sequencing could more accurately guide individualized treatment as the full drug resistance profile is obtained with a single test...
February 16, 2023: Research Square
https://read.qxmd.com/read/36824635/pro-and-contra-on-adjuvants-to-neuroaxial-anesthesia-and-peripheral-nerve-blocks
#4
REVIEW
Lada Kalagac Fabris
Modern approach in surgical treatment and in managing acute and chronic pain is nowadays more and more based on the implementation of all possible techniques of regional anesthesia (RA). Local anesthetics (LA) are needed to achieve standard regional anesthesia. Local anesthetics are primarily characterized by time constraints and duration of action, and depending on the amount applied, adverse effects on the cardiac and central nervous system may occur. Adjuvants are drugs used together with LA due to their synergistic effect, i...
September 2022: Acta Clinica Croatica
https://read.qxmd.com/read/36725452/clinical-pathways-in-the-management-of-the-obese-pre-and-postoperative-aspects
#5
REVIEW
S Guillerme, J Delarue, J Thereaux
INTRODUCTION: Bariatric surgery (BS) leads to substantial weight loss accompanied by reversal of several obesity-related co-morbidities and reduced mortality. However, surgery is associated with risks and its nearly irreversible characteristic requires a clearly established pre- and postoperative clinical pathway. In France, this pathway relies on recommendations made by the High Authority of Health (Haute Autorité de santé (HAS)) in 2009; an update is awaited in 2023. PREOPERATIVE ASPECTS: BS should be proposed only after failure of well-conducted medical treatment and is intended for patients whose body mass index (BMI) is ≥40kg/m2 or for those with BMI ≥35kg/m2 who also have co-morbidities amenable to improvement, and in whom there are no contra-indications, particularly, those related to general anesthesia or psychological factors...
January 30, 2023: Journal of Visceral Surgery
https://read.qxmd.com/read/36644744/adherence-to-who-criteria-on-drug-promotion-literature-an-exploratory-study-from-a-tertiary-healthcare-facility-in-south-west-nigeria
#6
JOURNAL ARTICLE
Joseph O Fadare, Iyanu Bankole, Adefunke Babatola, Oladele Simeon Olatunya, Felix Aina, Brian Godman
Introduction: In many low and middle-income countries (LMIC), drug promotional literature (DPL) remains one of the main sources of drug information for physicians. Studies conducted in many LMICs showed poor compliance to the WHO guidelines for ethical drug promotion especially in the area of information about excipients, adverse drug reactions, drug-drug interactions and contra-indications. These inadequacies in the information provided may mislead the prescriber with potential adverse consequences among patients using the medicines...
February 2023: Hospital Pharmacy
https://read.qxmd.com/read/36633813/pharmacokinetics-and-pharmacodynamic-of-alpelisib
#7
REVIEW
Bernard Royer, Courèche Guillaume Kaderbhaï, Antonin Schmitt
Advanced breast cancers are frequently hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Some of them harbor a mutation in PIK3CA, a gene encoding the PI3K catalytic subunit α of phosphatidyl-inositol 3-kinase (PI3K), which confers resistance to hormone therapy. Alpelisib is the first oral selective p110 [Formula: see text] PI3K inhibitor approved by FDA and EMA, in association with fulvestrant, based on PFS improvement as compared to fulvestrant alone. The aim of this review is to summarize and critically review the key aspects of alpelisib pharmacokinetics (PK) and pharmacodynamics (PD)...
January 12, 2023: Clinical Pharmacokinetics
https://read.qxmd.com/read/36484754/-inclisiran-leqvio%C3%A2-a-potent-cholesterol-lowering-agent-by-inhibiting-pcsk9-using-small-interfering-rna-based-innovative-therapy
#8
JOURNAL ARTICLE
A J Scheen, C Wallemacq, P Lancellotti
PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) inhibition has proven its interest to potentiate the cholesterol-lowering effects of statins. Indeed, this protein contributes to the intracellular degradation of LDL cholesterol receptors and thereby reduces their recycling and expression at the hepatocyte membrane. PCSK9 inhibition allows a major and sustained reduction of LDL cholesterol (LDL-c) in patients with familial hypercholesterolaemia or with established cardiovascular disease. Two monoclonal antibodies that inhibit the effect of PCSK9 are currently commercialized, alirocumab and evolocumab...
December 2022: Revue Médicale de Liège
https://read.qxmd.com/read/36443990/eurovisco-good-practice-recommendations-for-a-first-viscosupplementation-in-patients-with-knee-osteoarthritis
#9
JOURNAL ARTICLE
Thierry Conrozier, Demirhan Diraçoglù, Jordi Monfort, Xavier Chevalier, Hervé Bard, Dominique Baron, Jörg Jerosch, Alberto Migliore, Pascal Richette, Yves Henrotin
RATIONALE: Viscosupplementation (VS) with hyaluronic acid is widely used in the management of knee osteoarthritis. There is no clear recommendation on the decision-making to achieve VS. DESIGN: Based on extensive research of the literature and expert opinion, the members of the EUROVISCO (European Viscosupplementation Consensus Group) task force were asked to give their degree of agreement with 60 issues, using a Delphi method. RESULTS: The expert panel achieved unanimous agreement in favor of the following statements: It is recommended to assess pain on a visual or 10-point numeric scale before considering VS...
June 2023: Cartilage
https://read.qxmd.com/read/36442212/a-drug-utilization-and-drug-interaction-study-in-renal-transplant-patients-implications-for-an-urgent-need-for-drug-deprescribing
#10
JOURNAL ARTICLE
Kannan Sridharan, Shamik Shah, Ola Al Segai, Eman Mansoor, Mustafa Hammad, Eman Farid
BACKGROUND: Renal transplant patients receive several drugs concomitantly. OBJECTIVE: Limited literature exists evaluating the drug use in this population that is at high risk for drug-induced acute kidney injury and complications due to under-or over-dosage of immunosuppressant drugs due to drug-drug interactions. METHODS: A retrospective observational study was carried out in 269 renal transplant patients in whom either oral or parenteral drugs were evaluated...
November 17, 2022: International Journal of Risk & Safety in Medicine
https://read.qxmd.com/read/36113099/non-steroidal-anti-inflammatory-drugs-nsaids-in-cancer-pain-a-database-analysis-to-determine-recruitment-feasibility-for-a-clinical-trial
#11
JOURNAL ARTICLE
Andrew J Page, Katie Spencer, Matthew R Mulvey, Barry Ja Laird, Michael I Bennett
BACKGROUND: Insufficient evidence exists to support or refute use of NSAIDs for managing cancer pain. Palliative physicians support a placebo-controlled trial of NSAIDs as strong opioid adjuncts for cancer-induced bone pain as the most pragmatic design to benefit clinical practice. AIM: We aimed to determine patient numbers receiving palliative radiotherapy for cancer-induced bone pain, estimate the suitability of NSAID prescription and determine survival, guiding future trial feasibility...
October 2022: Palliative Medicine
https://read.qxmd.com/read/35837705/desmoid-tumors-who-when-and-how-to-treat
#12
REVIEW
Rabih Mikhael, Myles Smith, Dimitri Tzanis, Sarah Watson, Aisha B Miah, Sylvie Bonvalot
PURPOSE OF REVIEW: The objective of this article is to summarize new treatment strategies of desmoid tumors. RECENT FINDINGS: Desmoid tumor has an unpredictable evolution that may spontaneously regress or stabilize. A shift toward an initial frontline active surveillance has been acknowledged by experts. Surveillance monitoring should be performed frequently after the diagnosis to avoid missing a significant progression and then spaced in case of stabilization. Treatment is based on significant tumor growth or symptoms...
July 1, 2022: Current Opinion in Oncology
https://read.qxmd.com/read/35780391/potentially-inappropriate-medication-use-by-level-of-polypharmacy-among-us-veterans-49-64-and-65-70-years-old
#13
JOURNAL ARTICLE
Jordan Guillot, Christopher T Rentsch, Kirsha S Gordon, Amy C Justice, Julien Bezin
BACKGROUND: Potentially inappropriate medications (PIMs) are medications contra-indicated in particular circumstances. We sought to characterize PIMs by level of polypharmacy by age, sex, and race/ethnicity. METHODS: We performed a cross-sectional drug dispensing study using electronic health records available through the US Department of Veterans Affairs. We extracted pharmacy fill and refill records during fiscal year 2016 (i.e., October 1, 2015-September 30, 2016) for all patients aged 49-70 who accessed care in the preceding fiscal year...
October 2022: Pharmacoepidemiology and Drug Safety
https://read.qxmd.com/read/35618549/management-of-drug-drug-interactions-with-nirmatrelvir-ritonavir-in-patients-treated-for-covid-19-guidelines-from-the-french-society-of-pharmacology-and-therapeutics-sfpt
#14
JOURNAL ARTICLE
Florian Lemaitre, Matthieu Grégoire, Caroline Monchaud, Stéphane Bouchet, Béatrice Saint-Salvi, Elisabeth Polard
OBJECTIVES: Nirmatrelvir in association with ritonavir (PAXLOVID™, Pfizer) is an antiviral agent targeting the 3-chymotrypsin-like cysteine protease enzyme (3C-like protease or Mpro) which is a key enzyme of the viral cycle of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This combination with a well-known pharmacokinetic enhancer leads to a high risk for drug-drug interactions in a polymedicated elected population for treatment. The aim of this work was to provide recommendations on behalf of the national French society of pharmacology (French Society of Pharmacology and Therapeutics; SFPT), by suggesting optimal and pragmatic therapeutic strategies if nirmatrelvir/ritonavir is to be given together with drugs commonly used, in order to ensure secured physicians' prescription...
2022: Thérapie
https://read.qxmd.com/read/35390220/investigation-on-utility-of-some-novel-terpenes-on-transungual-delivery-of-fluconazole-for-the-management-of-onychomycosis
#15
JOURNAL ARTICLE
Syeda Nashvia Adin, Isha Gupta, Asad Ali, Mohd Aqil, Mohd Mujeeb, Yasmin Sultana
BACKGROUND: Onychomycosis, the most prevailing affliction of the nail, accounts for approximately 90% of the toenail infection worldwide. Owing to this infection, the affected patients experience reduced quality of their life as its awful appearance undermines their daily activities and social interactions. Onychomycosis is notoriously strenuous to cure. Systemic therapy, though effective, possess severe complication of toxicities, contra-indication, and drug-drug interaction. Albeit topical therapy is favorable to its localized effect, its potency relates to the effective concentration of the antifungal drugs achieved at the infection site...
April 7, 2022: Journal of Cosmetic Dermatology
https://read.qxmd.com/read/34599699/early-guideline-directed-medical-therapy-and-in-hospital-major-bleeding-risk-in-st-elevation-myocardial-infarction-patients-treated-with-percutaneous-coronary-intervention-findings-from-the-ccc-acs-project
#16
JOURNAL ARTICLE
Ziping Li, Pengfei Yang, Geru A, Haonan Sun, Hangkuan Liu, Xiwen Song, Zhengyang Jin, Linjie Li, Yongchen Hao, Yongle Li, Jing Liu, Dong Zhao, Xin Zhou, Qing Yang
PURPOSE: Previous reports demonstrated a bleeding avoidance potential of angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) and β-blocker. It remains unclear whether early guideline-directed medical therapy [GDMT, i.e., the combined use of β-blocker, angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) and statin] confers protection against bleeding in the setting of high-intensity antithrombotic therapy. METHODS: We assessed associations between the use of early (within the first 24 h) GDMT and in-hospital major bleeds, ischemic events and mortality among ST-elevation myocardial infarction (STEMI) patients treated with percutaneous coronary intervention (PCI) in the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome project...
October 2, 2021: Cardiovascular Drugs and Therapy
https://read.qxmd.com/read/34590982/effectiveness-of-ezetimibe-in-human-immunodeficiency-virus-patients-treated-for-hyperlipidaemia-a-systematic-review-and-meta-analysis
#17
JOURNAL ARTICLE
Nanguneri Nirmala, Esther E Avendano, Rebecca A Morin
OBJECTIVE: Systematic review and meta-analysis of lipid outcomes for human immunodeficiency virus (HIV)-positive or HIV-infected patients treated with ezetimibe. METHODS: We conducted a literature search from 1946 to 2021 for trials studying the effectiveness of ezetimibe in hyperlipidaemic HIV patients. We included trials of all designs in which HIV patients on highly active antiretroviral therapy (HAART)/non-nucleoside reverse transcriptase inhibitor (NNRTI) therapy had hyperlipidaemia, were treated with ezetimibe, and reported lipid outcomes...
February 2022: Infectious Diseases
https://read.qxmd.com/read/34414298/colchicine-for-prevention-of-vascular-inflammation-in-non-cardioembolic-stroke-convince-study-protocol-for-a-randomised-controlled-trial
#18
JOURNAL ARTICLE
Peter Kelly, Christian Weimar, Robin Lemmens, Sean Murphy, Francisco Purroy, Anita Arsovska, Natan M Bornstein, Anna Czlonkowska, Urs Fischer, Ana Catarina Fonseca, John Forbes, Michael D Hill, Dalius Jatuzis, Janika Kõrv, Christina Kruuse, Robert Mikulik, Paul J Nederkoorn, Martin O'Donnell, Peter Sandercock, David Tanne, Georgios Tsivgoulis, Cathal Walsh, David Williams, Marialuisa Zedde, Christopher I Price
Background: Inflammation contributes to unstable atherosclerotic plaque and stroke. In randomised trials in patients with coronary disease, canukinumab (an interleukin-1B antagonist) and colchicine (a tubulin inhibitor with pleiotropic anti-inflammatory effects) reduced recurrent vascular events.Hypothesis: Anti-inflammatory therapy with low-dose colchicine plus usual care will reduce recurrent vascular events in patients with non-severe, non-cardioembolic stroke and TIA compared with usual care alone...
June 2021: European Stroke Journal
https://read.qxmd.com/read/34380072/recommendations-regarding-cardiac-stereotactic-body-radiotherapy-for-treatment-refractory-ventricular-tachycardia
#19
JOURNAL ARTICLE
David Krug, Oliver Blanck, Nicolaus Andratschke, Matthias Guckenberger, Raphael Jumeau, Felix Mehrhof, Judit Boda-Heggemann, Katharina Seidensaal, Jürgen Dunst, Etienne Pruvot, Eberhard Scholz, Ardan M Saguner, Boris Rudic, Leif-Hendrik Boldt, Hendrik Bonnemeier
BACKGROUND: Ventricular tachycardia (VT) is a potentially lethal complication of structural heart disease. Despite optimal management, a subgroup of patients continue to suffer from recurrent VT. Recently, cardiac stereotactic body radiotherapy (CSBRT) has been introduced as a treatment option in patients with VT refractory to antiarrhythmic drugs and catheter ablation. OBJECTIVE: The purpose of this study was to establish an expert consensus regarding the conduct and use of CSBRT for refractory VT...
August 8, 2021: Heart Rhythm: the Official Journal of the Heart Rhythm Society
https://read.qxmd.com/read/34296400/how-to-tackle-the-diagnosis-and-treatment-in-the-diverse-scenarios-of-extrapulmonary-sarcoidosis
#20
REVIEW
Dominique Valeyre, Florence Jeny, Cécile Rotenberg, Diane Bouvry, Yurdagül Uzunhan, Pascal Sève, Hilario Nunes, Jean-François Bernaudin
Extrapulmonary sarcoidosis occurs in 30-50% of cases of sarcoidosis, most often in association with pulmonary involvement, and virtually any organ can be involved. Its incidence depends according to the organs considered, clinical phenotype, and history of sarcoidosis, but also on epidemiological factors like age, sex, geographic ancestry, and socio-professional factors. The presentation, symptomatology, organ dysfunction, severity, and lethal risk vary from and to patient even at the level of the same organ...
September 2021: Advances in Therapy
keyword
keyword
49045
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.